Anatara Lifesciences (ASX:ANR) received a patent for its Gastrointestinal ReProgramming (GaRP) product, under the invention title "Gastrointestinal Health Composition," according to a Tuesday filing with the Australian bourse.
The intellectual property protection, granted by the Australian Patent Office, has a 20-year term from Oct. 9, 2020, to Oct. 9, 2040, the filing said.
The GaRP product is a complementary medicine designed to tackle the root causes of chronic gastrointestinal conditions like irritable bowel syndrome and inflammatory bowel disease, per the filing.
Its shares fell 8% in afternoon trade Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.